loader image
Thursday, October 9, 2025
91.2 F
McAllen
- Advertisement -

Cipherome Leadership Visits DHR Health to Discuss the Value of Genetic-Based Study in Patients Undergoing Percutaneous Coronary Intervention

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

Edinburg, TX – Patients undergoing Percutaneous Coronary Intervention (PCI) or stent placement, after a stroke or heart attack require treatment that would reduce the risk of ischemic events without increasing the risk of bleeding. In addition to Aspirin, Plavix (Clopidogrel) is the most commonly used drug for this purpose and has been shown to reduce the risk of acute cardiac events and mortality.  To be effective, Plavix has to be activated in the liver, but some people have defective process thus reducing its therapeutic value.

DHR Health and DHR Health Institute for Research & Development are working with Cipherome, Inc., to use their genetic technology to determine if a patient undergoing PCI for coronary events has an intact pathway to metabolize Plavix. Over 90 patients have already been recruited in this study and a total of 350 patients will be recruited in the next few months.   

As the first gene-based study to be piloted in the Rio Grande Valley, Dr. Jane Chiang, chief medical officer and Jose Estabil, chief business officer at Cipherome, Inc., visited with DHR Health and DHR Health Institute for Research and Development leadership to discuss the value of this personalized medicine study that began back in December of 2020.  Cipherome, Inc. preferred South Texas for this pilot project to better understand how the genetic differences in Hispanic/Latino patients relate to the effectiveness and safety of medications used to treat them. 

- Advertisement -

“The use of this technology will allow the physicians at DHR Health to predict how a patient undergoing PCI will respond to Plavix therapy based on that patient’s genetic makeup” said Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development.  “This study continues to build on the DHR Health vision to practice advanced medicine and to bring the most innovative clinical care to the community”.  

For more information on research studies, please contact Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development at (956) 362-2387 or visit www.dhrresearch.org

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Urology Institute Expands Expertise with Dr. Kayvon Kian

DHR Health, one of the largest physician-owned hospitals in the United States, proudly serving the Rio Grande Valley since 1997, is excited to welcome Dr. Kayvon Kiani to our esteemed team at the DHR Health Urology Institute.

STHS Children’s Webinar on Bullying/Cyberbullying Prevention, Oct. 15th

Considered serious public health concerns, bullying and cyberbullying continue to rise at a concerning rate in the United States, resulting in widespread negative consequences for victims, perpetrators and bystanders.

STHS Children’s Receives $14,150 Donation from Dutch Bros

Mega Doctor News Planned or unplanned, a hospital stay can be nerve-wracking for...

STC & Region One ESC Open More Doors to High School Completion

Homeschooled for most of her life, Edcouch-Elsa senior Ana Trevino put her education on hold two years ago to care for her parents as they battled cancer and to step in as a second mother to her six younger siblings.
- Advertisement -
×